10:43 AM EDT, 09/29/2015 (MT Newswires) -- Resverlogix Corp. (RVX.TO) shares are up nearly 8% Tuesday after the company reported that its clinical and science teams, along with two members of the international clinical steering committee for the upcoming BETonMACE study, presented a Research and Development Update for RVX-208 "apabetalone" on September 25, 2015 in New York City.

Highlights from the presentation included an in depth analysis of the large unmet medical need in diabetes patients at high risk for secondary major adverse cardiovascular events. Senior Vice President of Clinical Development, Dr. Mike Sweeney, MD detailed the final design of the BETonMACE clinical trial, and Vice President of Scientific Development, Dr. Ewelina Kulikowski, PhD highlighted novel biology and findings from ongoing mechanistic studies focused on cardiovascular risk pathways and apabetalone's potential in reducing MACE.

Resverlogix's shares last traded at $1.95, up 7.7% since Monday's close.

Price: 1.95, Change: +0.14, Percent Change: +7.73